$-0.57 EPS Expected for Bellicum Pharmaceuticals, Inc. (BLCM)

July 14, 2018 - By Duane Lopez

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Logo

Analysts expect Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to report $-0.57 EPS on August, 14.They anticipate $0.17 EPS change or 22.97 % from last quarter’s $-0.74 EPS. After having $-0.68 EPS previously, Bellicum Pharmaceuticals, Inc.’s analysts see -16.18 % EPS growth. The stock increased 0.50% or $0.04 during the last trading session, reaching $8.09. About 279,158 shares traded. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has declined 34.37% since July 14, 2017 and is downtrending. It has underperformed by 46.94% the S&P500.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Ratings Coverage

Among 4 analysts covering Bellicum Pharmaceuticals (NASDAQ:BLCM), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bellicum Pharmaceuticals has $27.0 highest and $6.0 lowest target. $17.25’s average target is 113.23% above currents $8.09 stock price. Bellicum Pharmaceuticals had 5 analyst reports since January 31, 2018 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, April 11. The stock of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has “Hold” rating given on Wednesday, January 31 by Wells Fargo. The firm has “Outperform” rating given on Thursday, April 12 by Wells Fargo.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company has market cap of $346.84 million. It has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant ; BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It currently has negative earnings. The firm has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens.

More news for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) were recently published by: Seekingalpha.com, which released: “Biotech: Take It On The Run” on July 05, 2018. Nasdaq.com‘s article titled: “Analysis: Positioning to Benefit within Uranium Energy, Bellicum Pharmaceuticals, Tutor Perini, Maiden, Hill-Rom, and …” and published on June 15, 2018 is yet another important article.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: